<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578175</url>
  </required_header>
  <id_info>
    <org_study_id>110058</org_study_id>
    <nct_id>NCT00578175</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age</brief_title>
  <official_title>Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer blinded study is to provide information on vaccine
      immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when
      administered with Hepatitis A vaccine and Pneumococcal vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV)</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Seroresponse for antibodies to VZV is defined as the appearance post-vaccination of anti-VZV antibodies [concentration greater than or equal to the threshold of 75 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 25 mIU/mL before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Antibodies to Varicella Virus (VZV)</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroresponse for Antibodies to Mumps Virus</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Seroresponse for antibodies to mumps virus is defined as the appearance post-vaccination of anti-mumps virus antibodies [titer greater than or equal to the threshold of 51 Effective Doses (ED50)] in the serum of subjects below the assay cut-off value of 24 ED50 before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroresponse for Antibodies to Measles Virus</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Seroresponse for antibodies to measles virus is defined as the appearance post-vaccination of anti-measles virus antibodies [concentration greater than or equal to the threshold of 200 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 150 mIU/mL before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroresponse for Antibodies to Rubella Virus</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Seroresponse for antibodies to rubella virus is defined as the appearance post-vaccination of anti-rubella virus antibodies [concentration greater than or equal to the threshold of 10 international units per milliliter (IU/mL)] in the serum of subjects below the assay cut-off value of 4 IU/mL before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Antibodies to Hepatitis A Virus (HAV)</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers to Mumps Virus</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies to Measles Virus</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies to Rubella Virus</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response to Havrix®</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Vaccine response to Havrix® is defined as the appearance post-vaccination of anti-hepatitis A virus (anti-HAV) antibodies [concentration greater than or equal to 15 milli-international units per milliliter (mIU/mL)] in the serum of subjects seronegative before vaccination (concentration below the assay cut-off value of 15 mIU/mL) or having a 2-fold increase above the pre-vaccination concentration in subjects who were seropositive before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Cut-off value assessed include 0.05 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Cut-off value assessed include 0.2 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Cut-off value assessed include 0.5 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</measure>
    <time_frame>At Day 42 after vaccination</time_frame>
    <description>Cut-off value assessed include 1.0 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 4 day follow up period following vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and &gt; 39.5°C/103.1°F During the 15-day Follow up Period After Vaccination</measure>
    <time_frame>During the 15-day follow-up period following vaccination</time_frame>
    <description>Fever was measured rectally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and &gt; 39.5°C/103.1°F During the 43-day Follow-up Period After Vaccination</measure>
    <time_frame>During the 43-day follow-up period following vaccination</time_frame>
    <description>Fever was measured rectally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash</measure>
    <time_frame>During the 43-day follow-up period after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Investigator-confirmed Varicella-like Rash</measure>
    <time_frame>During the 43-day follow-up period after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling</measure>
    <time_frame>During the 43-day follow-up period after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling)</measure>
    <time_frame>During the 43-day follow-up period after vaccination</time_frame>
    <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Medically-attended adverse event covers any adverse event which received medical attention. Medical attention is defined as hospitalization, an emergency room visit or a visit to or from medical personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits</measure>
    <time_frame>For approximately 6 months (Day 0-180)</time_frame>
    <description>New onset chronic illnesses include autoimmune disorders, asthma, type I diabetes and allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>For approximately 6 months (Day 0-180)</time_frame>
    <description>Serious adverse events assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1851</enrollment>
  <condition>Varicella</condition>
  <condition>Rubella</condition>
  <condition>Mumps</condition>
  <condition>Measles</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Priorix-Tetra™ (MMRV vaccine 208136)</intervention_name>
    <description>One subcutaneous injection.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad®</intervention_name>
    <description>One subcutaneous injection.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix®</intervention_name>
    <description>Two intramuscular injections.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar®</intervention_name>
    <description>One intramuscular injection.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for whom the investigator believes their parents/guardians can and will
             comply with the requirements of the protocol.

          -  Male or female between 12 and 14 months of age at the time of first vaccination.

          -  Written informed consent obtained from the parent/guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Have previously received 3 doses of 7-valent pneumococcal conjugate vaccine within the
             first year of life.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             from 30 days prior to vaccination until 42 days after vaccination, except for
             influenza vaccine.

          -  Previous vaccination against measles, mumps, rubella and/or varicella.

          -  Previous vaccination against hepatitis A or receipt of a fourth dose of pneumococcal
             conjugate vaccine.

          -  History of measles, mumps, rubella and/or varicella/zoster diseases.

          -  Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior
             to the start of the study.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination, including human immunodeficiency virus
             infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures. Uncomplicated febrile convulsions are
             not an exclusion criterion.

          -  Residence in the same household as the following persons:

               -  New-born infants (0-4 weeks of age).

               -  Pregnant mother/women with a negative history of chickenpox disease and without
                  recorded vaccination against chickenpox.

               -  Pregnant women at or beyond 28 weeks gestation regardless of varicella
                  vaccination status or varicella disease history.

               -  Persons with known immunodeficiency.

          -  Acute disease at the time of enrolment. All vaccines can be administered to persons
             with a minor illness.

          -  Administration of polyclonal immunoglobulins and/or any blood products during the six
             months before entering the study or planned administration during the study period.

          -  Contra-indications to commercially available vaccines used in this study (Havrix®,
             Prevnar®, ProQuad®).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>14 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benton</city>
        <state>Arkansas</state>
        <zip>72015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westminster</city>
        <state>Colorado</state>
        <zip>80234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Opa Locka</city>
        <state>Florida</state>
        <zip>33054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <zip>30117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tifton</city>
        <state>Georgia</state>
        <zip>31794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>208 463 3126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeKalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fischers</city>
        <state>Indiana</state>
        <zip>46038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waukee</city>
        <state>Iowa</state>
        <zip>50263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ark City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Kentucky</state>
        <zip>40069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <zip>49024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richland</city>
        <state>Michigan</state>
        <zip>49083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brainerd</city>
        <state>Minnesota</state>
        <zip>56401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>White House Station</city>
        <state>New Jersey</state>
        <zip>08889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utica</city>
        <state>New York</state>
        <zip>13502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Norriton</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kittaning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, London A, Cambron P, Douha M, Nicholson O, da Costa C, Innis BL. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012 Aug;31(8):e133-40. doi: 10.1097/INF.0b013e318259fc8a.</citation>
    <PMID>22622699</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>March 5, 2010</results_first_submitted>
  <results_first_submitted_qc>August 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2010</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines</keyword>
  <keyword>Rubella</keyword>
  <keyword>Varicella Vaccine</keyword>
  <keyword>Children</keyword>
  <keyword>Humans</keyword>
  <keyword>Mumps</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Measles</keyword>
  <keyword>Combined Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110058</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>While the total numbers of subjects enrolled in the study was of 1851, the total number of subjects that entered the study was 1783. The remaining 67 subjects received a subject number but no vaccine dose and were therefore excluded from the analysis and group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Refrigerator-stored Priorix-Tetra™ Group</title>
          <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
        </group>
        <group group_id="P2">
          <title>Freezer-stored Priorix-Tetra™ Group</title>
          <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
        </group>
        <group group_id="P3">
          <title>ProQuad® Group</title>
          <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="705"/>
                <participants group_id="P2" count="689"/>
                <participants group_id="P3" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="635"/>
                <participants group_id="P2" count="646"/>
                <participants group_id="P3" count="365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Refrigerator-stored Priorix-Tetra™ Group</title>
          <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
        </group>
        <group group_id="B2">
          <title>Freezer-stored Priorix-Tetra™ Group</title>
          <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
        </group>
        <group group_id="B3">
          <title>ProQuad® Group</title>
          <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="705"/>
            <count group_id="B2" value="689"/>
            <count group_id="B3" value="389"/>
            <count group_id="B4" value="1783"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="0.58"/>
                    <measurement group_id="B2" value="12.3" spread="0.59"/>
                    <measurement group_id="B3" value="12.3" spread="0.61"/>
                    <measurement group_id="B4" value="12.3" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="186"/>
                    <measurement group_id="B4" value="888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV)</title>
        <description>Seroresponse for antibodies to VZV is defined as the appearance post-vaccination of anti-VZV antibodies [concentration greater than or equal to the threshold of 75 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 25 mIU/mL before vaccination.</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV)</title>
          <description>Seroresponse for antibodies to VZV is defined as the appearance post-vaccination of anti-VZV antibodies [concentration greater than or equal to the threshold of 75 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 25 mIU/mL before vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="630"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355"/>
                    <measurement group_id="O2" value="440"/>
                    <measurement group_id="O3" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Antibodies to Varicella Virus (VZV)</title>
        <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibodies to Varicella Virus (VZV)</title>
          <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>milli-international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="77.0" upper_limit="90.8"/>
                    <measurement group_id="O2" value="109.9" lower_limit="102.1" upper_limit="118.3"/>
                    <measurement group_id="O3" value="164.3" lower_limit="152.3" upper_limit="177.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroresponse for Antibodies to Mumps Virus</title>
        <description>Seroresponse for antibodies to mumps virus is defined as the appearance post-vaccination of anti-mumps virus antibodies [titer greater than or equal to the threshold of 51 Effective Doses (ED50)] in the serum of subjects below the assay cut-off value of 24 ED50 before vaccination.</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroresponse for Antibodies to Mumps Virus</title>
          <description>Seroresponse for antibodies to mumps virus is defined as the appearance post-vaccination of anti-mumps virus antibodies [titer greater than or equal to the threshold of 51 Effective Doses (ED50)] in the serum of subjects below the assay cut-off value of 24 ED50 before vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
                <count group_id="O2" value="531"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491"/>
                    <measurement group_id="O2" value="498"/>
                    <measurement group_id="O3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroresponse for Antibodies to Measles Virus</title>
        <description>Seroresponse for antibodies to measles virus is defined as the appearance post-vaccination of anti-measles virus antibodies [concentration greater than or equal to the threshold of 200 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 150 mIU/mL before vaccination.</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroresponse for Antibodies to Measles Virus</title>
          <description>Seroresponse for antibodies to measles virus is defined as the appearance post-vaccination of anti-measles virus antibodies [concentration greater than or equal to the threshold of 200 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 150 mIU/mL before vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="626"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616"/>
                    <measurement group_id="O2" value="633"/>
                    <measurement group_id="O3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroresponse for Antibodies to Rubella Virus</title>
        <description>Seroresponse for antibodies to rubella virus is defined as the appearance post-vaccination of anti-rubella virus antibodies [concentration greater than or equal to the threshold of 10 international units per milliliter (IU/mL)] in the serum of subjects below the assay cut-off value of 4 IU/mL before vaccination.</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroresponse for Antibodies to Rubella Virus</title>
          <description>Seroresponse for antibodies to rubella virus is defined as the appearance post-vaccination of anti-rubella virus antibodies [concentration greater than or equal to the threshold of 10 international units per milliliter (IU/mL)] in the serum of subjects below the assay cut-off value of 4 IU/mL before vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616"/>
                    <measurement group_id="O2" value="622"/>
                    <measurement group_id="O3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Antibodies to Hepatitis A Virus (HAV)</title>
        <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibodies to Hepatitis A Virus (HAV)</title>
          <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>milli-international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="37.1" upper_limit="44.2"/>
                    <measurement group_id="O2" value="40.3" lower_limit="37.0" upper_limit="44.0"/>
                    <measurement group_id="O3" value="40.0" lower_limit="35.7" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F</title>
        <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F</title>
          <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>micrograms per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="461"/>
                <count group_id="O2" value="468"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S.Pneu.4 (n= 461, 463, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="3.10" upper_limit="3.63"/>
                    <measurement group_id="O2" value="3.31" lower_limit="3.04" upper_limit="3.59"/>
                    <measurement group_id="O3" value="3.02" lower_limit="2.72" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S.Pneu.6B (n= 460, 464, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" lower_limit="5.16" upper_limit="6.19"/>
                    <measurement group_id="O2" value="5.91" lower_limit="5.40" upper_limit="6.45"/>
                    <measurement group_id="O3" value="5.43" lower_limit="4.90" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S.Pneu.9V (n=461, 468, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.81" lower_limit="5.37" upper_limit="6.29"/>
                    <measurement group_id="O2" value="5.66" lower_limit="5.23" upper_limit="6.13"/>
                    <measurement group_id="O3" value="5.54" lower_limit="5.02" upper_limit="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S.Pneu.14 (n= 460, 465, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" lower_limit="8.99" upper_limit="10.50"/>
                    <measurement group_id="O2" value="9.54" lower_limit="8.81" upper_limit="10.34"/>
                    <measurement group_id="O3" value="8.96" lower_limit="8.07" upper_limit="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S.Pneu.18C (n= 458, 465, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" lower_limit="5.04" upper_limit="6.01"/>
                    <measurement group_id="O2" value="5.80" lower_limit="5.30" upper_limit="6.34"/>
                    <measurement group_id="O3" value="5.51" lower_limit="4.95" upper_limit="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S.Pneu.19F (n= 454, 460, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="2.32" upper_limit="2.74"/>
                    <measurement group_id="O2" value="2.52" lower_limit="2.32" upper_limit="2.73"/>
                    <measurement group_id="O3" value="2.31" lower_limit="2.06" upper_limit="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S.Pneu.23F (n= 459, 464, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.10" lower_limit="9.22" upper_limit="11.06"/>
                    <measurement group_id="O2" value="10.85" lower_limit="9.87" upper_limit="11.91"/>
                    <measurement group_id="O3" value="9.79" lower_limit="8.65" upper_limit="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers to Mumps Virus</title>
        <description>Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum.</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers to Mumps Virus</title>
          <description>Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="601"/>
                <count group_id="O3" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.4" lower_limit="202.5" upper_limit="244.3"/>
                    <measurement group_id="O2" value="224.6" lower_limit="206.9" upper_limit="243.9"/>
                    <measurement group_id="O3" value="253.1" lower_limit="222.7" upper_limit="287.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies to Measles Virus</title>
        <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibodies to Measles Virus</title>
          <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>milli-international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="626"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4723.1" lower_limit="4436.4" upper_limit="5028.4"/>
                    <measurement group_id="O2" value="4650.3" lower_limit="4430.9" upper_limit="4880.5"/>
                    <measurement group_id="O3" value="4207.1" lower_limit="3823.3" upper_limit="4629.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies to Rubella Virus</title>
        <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibodies to Rubella Virus</title>
          <description>Concentrations are given as Geometric Mean Concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>International units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" lower_limit="55.9" upper_limit="64.1"/>
                    <measurement group_id="O2" value="57.9" lower_limit="54.4" upper_limit="61.7"/>
                    <measurement group_id="O3" value="71.4" lower_limit="65.5" upper_limit="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response to Havrix®</title>
        <description>Vaccine response to Havrix® is defined as the appearance post-vaccination of anti-hepatitis A virus (anti-HAV) antibodies [concentration greater than or equal to 15 milli-international units per milliliter (mIU/mL)] in the serum of subjects seronegative before vaccination (concentration below the assay cut-off value of 15 mIU/mL) or having a 2-fold increase above the pre-vaccination concentration in subjects who were seropositive before vaccination.</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Response to Havrix®</title>
          <description>Vaccine response to Havrix® is defined as the appearance post-vaccination of anti-hepatitis A virus (anti-HAV) antibodies [concentration greater than or equal to 15 milli-international units per milliliter (mIU/mL)] in the serum of subjects seronegative before vaccination (concentration below the assay cut-off value of 15 mIU/mL) or having a 2-fold increase above the pre-vaccination concentration in subjects who were seropositive before vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="345"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
        <description>Cut-off value assessed include 0.05 micrograms per milliliter (µg/mL).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
          <description>Cut-off value assessed include 0.05 micrograms per milliliter (µg/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="461"/>
                <count group_id="O2" value="468"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-S.Pneu-4 (n= 461, 463, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-6B (n= 460, 464, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-9V (n= 461, 468, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461"/>
                    <measurement group_id="O2" value="468"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-14 (n= 460, 465, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-18C (n= 458, 465, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-19F (n= 454, 460, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454"/>
                    <measurement group_id="O2" value="460"/>
                    <measurement group_id="O3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-23F (n= 459, 464, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="464"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
        <description>Cut-off value assessed include 0.2 micrograms per milliliter (µg/mL).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
          <description>Cut-off value assessed include 0.2 micrograms per milliliter (µg/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="461"/>
                <count group_id="O2" value="468"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-S.Pneu-4 (n= 461, 463, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-6B (n= 460, 464, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="460"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-9V (n= 461, 468, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461"/>
                    <measurement group_id="O2" value="468"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-14 (n= 460, 465, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-18C (n= 458, 465, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="464"/>
                    <measurement group_id="O3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-19F (n= 454, 460, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451"/>
                    <measurement group_id="O2" value="459"/>
                    <measurement group_id="O3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-23F (n= 459, 464, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="464"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
        <description>Cut-off value assessed include 0.5 micrograms per milliliter (µg/mL).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
          <description>Cut-off value assessed include 0.5 micrograms per milliliter (µg/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="461"/>
                <count group_id="O2" value="468"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-S.Pneu-4 (n= 461, 463, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="459"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-6B (n= 460, 464, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453"/>
                    <measurement group_id="O2" value="459"/>
                    <measurement group_id="O3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-9V (n= 461, 468, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="466"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-14 (n= 460, 465, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="464"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-18C (n= 458, 465, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-19F (n= 454, 460, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431"/>
                    <measurement group_id="O2" value="448"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-23F (n= 459, 464, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="462"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
        <description>Cut-off value assessed include 1.0 micrograms per milliliter (µg/mL).</description>
        <time_frame>At Day 42 after vaccination</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value</title>
          <description>Cut-off value assessed include 1.0 micrograms per milliliter (µg/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="461"/>
                <count group_id="O2" value="468"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-S.Pneu-4 (n= 461, 463, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                    <measurement group_id="O2" value="423"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-6B (n= 460, 464, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442"/>
                    <measurement group_id="O2" value="453"/>
                    <measurement group_id="O3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-9V (n= 461, 468, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="450"/>
                    <measurement group_id="O2" value="459"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-14 (n= 460, 465, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-18C (n= 458, 465, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446"/>
                    <measurement group_id="O2" value="455"/>
                    <measurement group_id="O3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-19F (n= 454, 460, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                    <measurement group_id="O2" value="390"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-S.Pneu-23F (n= 459, 464, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446"/>
                    <measurement group_id="O2" value="458"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During the 4 day follow up period following vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="673"/>
                <count group_id="O2" value="666"/>
                <count group_id="O3" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and &gt; 39.5°C/103.1°F During the 15-day Follow up Period After Vaccination</title>
        <description>Fever was measured rectally.</description>
        <time_frame>During the 15-day follow-up period following vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and &gt; 39.5°C/103.1°F During the 15-day Follow up Period After Vaccination</title>
          <description>Fever was measured rectally.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="668"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 38.0°C/100.4°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="241"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 39.5°C/103.1°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and &gt; 39.5°C/103.1°F During the 43-day Follow-up Period After Vaccination</title>
        <description>Fever was measured rectally.</description>
        <time_frame>During the 43-day follow-up period following vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and &gt; 39.5°C/103.1°F During the 43-day Follow-up Period After Vaccination</title>
          <description>Fever was measured rectally.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="668"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 38.0°C/100.4°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="301"/>
                    <measurement group_id="O3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 39.5°C/103.1°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash</title>
        <time_frame>During the 43-day follow-up period after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash</title>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="668"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Investigator-confirmed Varicella-like Rash</title>
        <time_frame>During the 43-day follow-up period after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Investigator-confirmed Varicella-like Rash</title>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="668"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling</title>
        <time_frame>During the 43-day follow-up period after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling</title>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="668"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling)</title>
        <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Medically-attended adverse event covers any adverse event which received medical attention. Medical attention is defined as hospitalization, an emergency room visit or a visit to or from medical personnel.</description>
        <time_frame>During the 43-day follow-up period after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling)</title>
          <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Medically-attended adverse event covers any adverse event which received medical attention. Medical attention is defined as hospitalization, an emergency room visit or a visit to or from medical personnel.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="705"/>
                <count group_id="O2" value="689"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unsolicited adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="332"/>
                    <measurement group_id="O3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits</title>
        <description>New onset chronic illnesses include autoimmune disorders, asthma, type I diabetes and allergies.</description>
        <time_frame>For approximately 6 months (Day 0-180)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits</title>
          <description>New onset chronic illnesses include autoimmune disorders, asthma, type I diabetes and allergies.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="705"/>
                <count group_id="O2" value="689"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New onsets of chronic diseases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency room visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events</title>
        <description>Serious adverse events assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>For approximately 6 months (Day 0-180)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Refrigerator-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O2">
            <title>Freezer-stored Priorix-Tetra™ Group</title>
            <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad® Group</title>
            <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events</title>
          <description>Serious adverse events assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="705"/>
                <count group_id="O2" value="689"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Events collected by systematic assessment are reported for subjects with a symptom diary card available.
Events collected by non-systematic method are reported for the Total Vaccinated Cohort.</desc>
      <group_list>
        <group group_id="E1">
          <title>Refrigerator-stored Priorix-Tetra™ Group</title>
          <description>Subjects received at day 0 a single dose of refrigerator-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
        </group>
        <group group_id="E2">
          <title>Freezer-stored Priorix-Tetra™ Group</title>
          <description>Subjects received at day 0 a single dose of freezer-stored Priorix-Tetra™ subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At Day 180 they received a second dose of Havrix® intramuscularly in the left thigh.</description>
        </group>
        <group group_id="E3">
          <title>ProQuad® Group</title>
          <description>Subjects received at day 0 a single dose of ProQuad® subcutaneously in the right upper arm co-administered with a single dose of Havrix® and Prevnar® intramuscularly in the left and right thigh respectively. At day 180 they received a second dose of Havrix® intramuscularly.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (unspecified)">Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental drug intake by child</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Hpoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Primitive neuroectodermal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Autism spectrum disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="338" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="332" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="673"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="666"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="673"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="666"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="673"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="666"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="312" subjects_at_risk="676"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="668"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="676"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="668"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>Uper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="705"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

